BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18727626)

  • 41. A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn.
    Hadley AG
    Vox Sang; 1998; 74 Suppl 2():375-83. PubMed ID: 9704470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Management of feto-maternal red cell allo-immunizations].
    Bricca P; Guinchard E; Guitton Bliem C
    Transfus Clin Biol; 2011 Apr; 18(2):269-76. PubMed ID: 21397546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rhesus Negative Woman Transfused With Rhesus Positive Blood: Subsequent Normal Pregnancy Without Anti D production.
    Maya ET; Buntugu KA; Pobee F; Srofenyoh EK
    Ghana Med J; 2015 Mar; 49(1):60-3. PubMed ID: 26339087
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Mechanism of action of anti-D-gamma globulin in preventing rhesus alloimmunization in the pregnant woman and hemolytic disease of the newborn infant].
    Vŭlcheva B; Spasova K
    Akush Ginekol (Sofiia); 1985; 24(2):73-6. PubMed ID: 2990248
    [No Abstract]   [Full Text] [Related]  

  • 45. RhD hemolytic disease of the newborn.
    Bowman JM
    N Engl J Med; 1998 Dec; 339(24):1775-7. PubMed ID: 9845715
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of Anti-D titers in RhD-negative pregnant women on fetuses and newborns: A retrospective study.
    Tang TH; Guo CY; Li XY; Hu YX; Liu WK; Yu MX
    Pediatr Neonatol; 2024 May; 65(3):288-292. PubMed ID: 37957047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prevention of fetomaternal rhesus-D allo-immunization. Perspectives].
    Cortey A; Brossard Y; Beliard R; Bourel D
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S119-1S122. PubMed ID: 16495837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rh(D) haemolytic disease of the newborn: the changing scene.
    Urbaniak SJ
    Br Med J (Clin Res Ed); 1985 Jul; 291(6487):4-6. PubMed ID: 2990630
    [No Abstract]   [Full Text] [Related]  

  • 49. [The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn].
    Starcević M; Mataija M; Sović D; Dodig J; Matijević R; Kukuruzović M
    Acta Med Croatica; 2011 Mar; 65(1):49-54. PubMed ID: 21568074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation of the Center for Rh-negative Mothers. Hospital Paula Jaraquemada (3 years)].
    Krug A; Bianchi R; Pérez N; Ilabaca G; Farías S; Rojas E
    Rev Chil Obstet Ginecol; 1981; 46(4):206-14. PubMed ID: 6099901
    [No Abstract]   [Full Text] [Related]  

  • 51. Anti-D in a mother, hemizygous for the variant RHD*DNB gene, associated with hemolytic disease of the fetus and newborn.
    Quantock KM; Lopez GH; Hyland CA; Liew YW; Flower RL; Niemann FJ; Joyce A
    Transfusion; 2017 Aug; 57(8):1938-1943. PubMed ID: 28639307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monoclonal anti-D for immunoprophylaxis.
    Scott ML
    Vox Sang; 2001 Nov; 81(4):213-8. PubMed ID: 11903995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of preimplantation genetic diagnosis in the management of severe rhesus alloimmunization: first unaffected pregnancy: case report.
    Seeho SK; Burton G; Leigh D; Marshall JT; Persson JW; Morris JM
    Hum Reprod; 2005 Mar; 20(3):697-701. PubMed ID: 15661826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preventing RhD haemolytic disease of the newborn.
    van Dijk B
    BMJ; 1997 Dec; 315(7121):1480-1. PubMed ID: 9420481
    [No Abstract]   [Full Text] [Related]  

  • 56. Hemolytic disease of the fetus and newborn due to multiple maternal antibodies.
    Markham KB; Rossi KQ; Nagaraja HN; O'Shaughnessy RW
    Am J Obstet Gynecol; 2015 Jul; 213(1):68.e1-68.e5. PubMed ID: 25644438
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.
    Kumpel BM
    Vox Sang; 2007 Aug; 93(2):99-111. PubMed ID: 17683353
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of haemolytic diseases of the newborn due to anti-D.
    Br Med J (Clin Res Ed); 1981 Feb; 282(6265):676-7. PubMed ID: 6781610
    [No Abstract]   [Full Text] [Related]  

  • 59. RhD haemolytic disease of the fetus and the newborn.
    Urbaniak SJ; Greiss MA
    Blood Rev; 2000 Mar; 14(1):44-61. PubMed ID: 10805260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin.
    Daniels G; Finning K; Martin P; Summers J
    Transfus Clin Biol; 2007 Dec; 14(6):568-71. PubMed ID: 18436463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.